Key Points
- Apogee CEO Michael Thomas Henderson sold 20,000 shares on Feb. 11 at an average price of $63.35 for proceeds of $1.267M, leaving him with 1,172,987 shares (a 1.68% reduction in his position).
- The Feb. 11 sale continues a recent pattern of insider disposals by Henderson, who also sold 20,000 shares on Jan. 14 (at $81.11), 20,000 on Dec. 10 (at $75.38) and 40,000 on Dec. 4 (at $75.01).
- Analysts show a consensus Moderate Buy with an average target of $104.58 (individual targets up to $133), while Apogee has a $4.63B market cap, a 52‑week range of $26.20–$84.56 and roughly 79% institutional ownership.
Apogee Therapeutics Inc. (NASDAQ:APGE - Get Free Report) CEO Michael Thomas Henderson sold 20,000 shares of the company's stock in a transaction dated Wednesday, February 11th. The stock was sold at an average price of $63.35, for a total transaction of $1,267,000.00. Following the transaction, the chief executive officer owned 1,172,987 shares in the company, valued at approximately $74,308,726.45. This trade represents a 1.68% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Michael Thomas Henderson also recently made the following trade(s):
- On Wednesday, January 14th, Michael Thomas Henderson sold 20,000 shares of Apogee Therapeutics stock. The stock was sold at an average price of $81.11, for a total transaction of $1,622,200.00.
- On Wednesday, December 10th, Michael Thomas Henderson sold 20,000 shares of Apogee Therapeutics stock. The shares were sold at an average price of $75.38, for a total transaction of $1,507,600.00.
- On Thursday, December 4th, Michael Thomas Henderson sold 40,000 shares of Apogee Therapeutics stock. The stock was sold at an average price of $75.01, for a total transaction of $3,000,400.00.
Apogee Therapeutics Stock Performance
NASDAQ:APGE opened at $67.78 on Friday. The company has a market cap of $4.63 billion, a price-to-earnings ratio of -15.47 and a beta of 1.42. The stock's fifty day moving average price is $74.39 and its two-hundred day moving average price is $57.22. Apogee Therapeutics Inc. has a 52-week low of $26.20 and a 52-week high of $84.56.
Analysts Set New Price Targets
Several research analysts have recently issued reports on the stock. Jefferies Financial Group reaffirmed a "buy" rating and issued a $95.00 target price on shares of Apogee Therapeutics in a research note on Monday, February 2nd. Stifel Nicolaus set a $133.00 price objective on shares of Apogee Therapeutics in a research note on Tuesday, January 6th. Wall Street Zen cut shares of Apogee Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, December 6th. Weiss Ratings reissued a "sell (d-)" rating on shares of Apogee Therapeutics in a research note on Wednesday, January 21st. Finally, Deutsche Bank Aktiengesellschaft began coverage on Apogee Therapeutics in a research report on Tuesday, December 9th. They issued a "buy" rating and a $103.00 price target on the stock. Three research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, Apogee Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $104.58.
View Our Latest Analysis on Apogee Therapeutics
Institutional Investors Weigh In On Apogee Therapeutics
Several hedge funds have recently bought and sold shares of the company. Wellington Management Group LLP raised its stake in shares of Apogee Therapeutics by 24.1% in the 3rd quarter. Wellington Management Group LLP now owns 4,723,701 shares of the company's stock valued at $187,673,000 after purchasing an additional 917,991 shares during the period. Vanguard Group Inc. raised its position in Apogee Therapeutics by 27.3% in the 4th quarter. Vanguard Group Inc. now owns 2,857,824 shares of the company's stock valued at $215,709,000 after buying an additional 612,193 shares during the last quarter. State Street Corp lifted its stake in Apogee Therapeutics by 2.1% in the 4th quarter. State Street Corp now owns 1,690,186 shares of the company's stock valued at $127,575,000 after acquiring an additional 34,638 shares in the last quarter. Paradigm Biocapital Advisors LP boosted its position in Apogee Therapeutics by 58.7% during the 3rd quarter. Paradigm Biocapital Advisors LP now owns 1,521,757 shares of the company's stock worth $60,459,000 after acquiring an additional 563,127 shares during the last quarter. Finally, Alliancebernstein L.P. grew its stake in shares of Apogee Therapeutics by 2.2% during the 3rd quarter. Alliancebernstein L.P. now owns 1,419,132 shares of the company's stock worth $56,382,000 after acquiring an additional 30,983 shares in the last quarter. 79.04% of the stock is currently owned by institutional investors and hedge funds.
About Apogee Therapeutics
(
Get Free Report)
Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.
The company's lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
